𝙱𝚒𝚘𝙷𝚘𝚛𝚘𝚜𝚌𝚘𝚙𝚎

This is an interpretation based on divination and should not be considered investment advice.

[𝙱𝚒𝚘𝙷𝚘𝚛𝚘𝚜𝚌𝚘𝚙𝚎 @Biohoroscope]

If you’re interested in my astrology readings, reply with a ticker you’re curious about. I’ll read it as much as I can.

[𝙱𝚒𝚘𝙷𝚘𝚛𝚘𝚜𝚌𝚘𝚙𝚎 @Biohoroscope]

@idalopirdine The stars told me that, based on the movements of Jupiter, Mercury, and Neptune, an explanation will likely be given around June 20 to June 28, bringing temporary relief.

[𝙱𝚒𝚘𝙷𝚘𝚛𝚘𝚜𝚌𝚘𝚙𝚎 @Biohoroscope]

$QURE

I see 2026 as a year when the part of the market that had been dreaming too much is pulled back into reality.

The period around October 20–27 looks especially important in 2026. Jupiter squares natal Saturn, while Saturn once again conjuncts natal Uranus. The theme from May comes back again.

This looks negative-leaning to me.

Not only the U.S. route, but also the U.K. route may face conditions or requests for additional confirmation, and the optimism that had been forming since May appears to break down.

Basically, I do not see AMT-130 being approved in 2026. I do not see it in 2027 either.

If I had to point to something, July 2027 does show some kind of positive response or recovery in corporate value, but it does not look like a major event that would fundamentally change the company’s value, such as an approval.

In Vedic astrology as well, QURE entered its Venus–Rahu period in July 2025. Venus lifts social reputation, fame, and market value, while Rahu indicates excessive expectations and being tossed around by external factors.

This continues until July 2028.

After that, it enters the Venus–Jupiter period, and that looks much more suitable for “formal expansion,” “approval,” and “commercialization.”

[𝙱𝚒𝚘𝙷𝚘𝚛𝚘𝚜𝚌𝚘𝚙𝚎 @Biohoroscope]

$ABVX

I read that $ABVX will clearly recover from the current safety concerns around August 13 to August 25.

From late June to early July, Jupiter forms a harmonious aspect to natal Saturn, which seems to temporarily ease the safety issue. However, from mid-July to early August, Saturn forms a square to natal Pluto, entering a period where anxiety is likely to arise not only around safety, but also around dialogue with regulators.

After falling through that phase, the recovery appears to come between August 13 and August 25. Mars stimulates natal Mars and the Sun, while Jupiter also moves onto the Ascendant. This is a configuration that suggests an improvement in how the company is perceived.

From around this point, $ABVX is likely to be re-evaluated not as a “scary stock,” but as an “oversold stock with strong data.”

[𝙱𝚒𝚘𝙷𝚘𝚛𝚘𝚜𝚌𝚘𝚙𝚎 @Biohoroscope]

$ABVX
The most likely acquisition window looks like late September to late October 2026.

In Western astrology, Jupiter starts moving over ABVX’s natal Venus and Jupiter from late September.

This company chart already has a strong 1st-house Venus–Jupiter conjunction, which tends to indicate corporate appeal, valuation, buyability, brand value, and acquisition premium. Then, from late September to early October 2026, transiting Jupiter returns to that point.

In Vedic astrology as well, the period after September 21 looks decisive.

Around September 21, 2026, the dasha shifts from:

Rahu–Saturn period → Rahu–Mercury period

Until September 2026, the theme looks like:

“There are acquisition rumors, but review processes, restrictions, and real-world conditions are heavy.”

After September 21, it starts to look more like:

“The company enters a phase of negotiation, contracts, and information disclosure.”

In Four Pillars of Destiny, 2026 itself points to a year of “sale” or “monetization of value.”

In this chart, the Day Master is Gui Water.

2026 is Bing Wu, and the relevant Ten God is Direct Wealth. However, the Twelve Stages show Jue, or “Termination,” so rather than simple growth, the nuance is more like:

“One form comes to an end, and the company shifts into another form.”

[𝙱𝚒𝚘𝙷𝚘𝚛𝚘𝚜𝚌𝚘𝚙𝚎 @Biohoroscope]

$ASTS
“But if the numbers or implementation details lack sufficient backing, it could easily be sold off later.”

[𝙱𝚒𝚘𝙷𝚘𝚛𝚘𝚜𝚌𝚘𝚙𝚎 @Biohoroscope]

For $ASTS , the period from mid-May to mid-June is one in which dreams and expectations may expand, but overconfidence should be avoided.

Around May 15: Jupiter square Venus
Around May 18: Jupiter trine Neptune
Around June 13: Jupiter sextile the ASC
Around June 14: Jupiter opposite Pluto
This is a configuration in which dreams, massive markets, future visions, major partnerships, financing, and expectations tend to swell.
It paints a very favorable picture.
However, because Jupiter and Neptune are involved, there is also a risk that the market dreams too much.

If good news comes out during this period, the stock price is likely to react strongly.

But if the numbers or implementation details lack sufficient backing, it could easily be sold off later.

[𝙱𝚒𝚘𝙷𝚘𝚛𝚘𝚜𝚌𝚘𝚙𝚎 @Biohoroscope]

$BAER
Around May 25, Pluto again makes a powerful contact with the Sun. This is a timing when the company’s fundamental theme becomes exposed to the market. Then, from late May through late June, Jupiter forms trines to natal Neptune and the Moon, and also opposes Pluto.

This looks highly newsworthy. Expectations, attention, narrative, social relevance, and thematic appeal expand. It may manifest as large orders, public-sector projects, seasonal demand, disaster/climate/aviation/infrastructure-related attention, or media exposure.

However, the Jupiter–Pluto interaction can create explosive stock-price potential, while also producing excessive expectations and sharp rallies followed by sharp drops.

There is a possibility that things become quite dramatic once again from late July to mid-August.

Around July 25, Jupiter opposes the natal Sun. This is a configuration where the company is “strongly illuminated from the outside.” The company becomes noticed, anticipated, and talked about. However, because this is an opposition, market attention may become too intense, whether in a positive or negative direction.

Around August 17, Uranus trines the natal Sun. This is very favorable. It suggests sudden positive developments, a breakthrough in technology, operations, communications, mobility, aviation/transportation-related areas, or a moment when value that had previously been overlooked is suddenly recognized.

For this company, May to June looks like the first wave, while late July to mid-August looks like the second wave.

[Anp🅰️nman @spacanpanman]

$BAER: Super Scooper summer rally inbound?

[𝙱𝚒𝚘𝙷𝚘𝚛𝚘𝚜𝚌𝚘𝚙𝚎 @Biohoroscope]

$LUNR

The periods around July 17–20 and November 7–13 are especially strong.

In July, Uranus trine, Pluto conjunction, and Jupiter opposition to the natal Mercury all occur around the same time. For a company, Mercury represents IR, announcements, contracts, technical explanations, media exposure, and milestone disclosures. With Pluto conjunct Mercury, this is unlikely to be just ordinary news; it is more likely to be information that changes the company’s image itself.

Around August 5, Jupiter trines the natal Moon. Around August 9, Jupiter trines the natal Jupiter. Around September 2, Jupiter sextiles the natal Mars. Around September 16, Jupiter trines the ASC. This suggests that material released between May and July may be reassessed positively in August and September. If the pattern is “initially doubted, then later bought,” this period fits very well.

What should not be overlooked is October to November. This is the major judgment phase.

Around October 10, Saturn again squares the MC. Around October 27, the Node conjoins the natal Saturn. Around November 11, the Node conjoins the natal Sun. Around November 13, Jupiter opposes the natal Sun.

The success or failure of a major project is likely to surface in a fateful way. From the chart, the second half of 2026—especially November—looks like a period when the market’s evaluation framework for the company may change.

As an astrological reading, $LUNR ’s 2026 theme is not simply “Can it go to the Moon?” but rather “Can it be recognized by the market as a lunar infrastructure company?”

[𝙱𝚒𝚘𝙷𝚘𝚛𝚘𝚜𝚌𝚘𝚙𝚎 @Biohoroscope]

For $ASTS , the period from mid-May to mid-June is one in which dreams and expectations may expand, but overconfidence should be avoided.

Around May 15: Jupiter square Venus
Around May 18: Jupiter trine Neptune
Around June 13: Jupiter sextile the ASC
Around June 14: Jupiter opposite Pluto
This is a configuration in which dreams, massive markets, future visions, major partnerships, financing, and expectations tend to swell.
It paints a very favorable picture.
However, because Jupiter and Neptune are involved, there is also a risk that the market dreams too much.

If good news comes out during this period, the stock price is likely to react strongly.

But if the numbers or implementation details lack sufficient backing, it could easily be sold off later.

[𝙱𝚒𝚘𝙷𝚘𝚛𝚘𝚜𝚌𝚘𝚙𝚎 @Biohoroscope]

$ASTS

For BlueBird 7 in April, Mercury, Mars, Saturn, and Neptune were indicating failure.

The next launch is in June. Around mid-June, Jupiter forms a sextile to the ASC and is roughly opposing Pluto, suggesting that the company’s presence will expand in the market. The ASC represents the company itself, the spacecraft, its visible form, and the way it steps out into the world. With Jupiter forming a supportive aspect to it, this strongly suggests “coming into public view,” “the spacecraft moving forward,” and “gaining attention and expanding.”

As a space-based communications infrastructure company, its “public stage” appears to be activated.

Recovering from April looks relatively easy.

[𝙱𝚒𝚘𝙷𝚘𝚛𝚘𝚜𝚌𝚘𝚙𝚎 @Biohoroscope]

$CGON

Following the turbulent period from June 11 to June 30, the company enters a phase from July 23 to July 30 in which “market expectations” may swell considerably. Astrologically, this period leans positive, but even if the stock rises, it is unlikely to be a smooth move and could easily become overheated.

July 23: Jupiter conjuncts the natal Moon.

July 24: Jupiter opposes the natal Sun.

July 30: Jupiter squares natal Jupiter.

August 12 to August 28 is important.

August 12: Solar eclipse.

August 28: The lunar eclipse comes close to opposing natal Saturn.

For this company, the second half of August looks heavy, with a lunar eclipse involving Saturn. This makes it easier for themes such as development plans, regulation, responsibility, trial design, financing, and realistic constraints to come to the surface.

This is not so much a period when dreams expand.

Rather, it is a date when the company is tested on whether it can withstand reality.

[𝙱𝚒𝚘𝙷𝚘𝚛𝚘𝚜𝚌𝚘𝚙𝚎 @Biohoroscope]

$CGON: June 11–June 30 looks like an important window.

June 11: Pluto re-hits the natal Sun
June 22: Pluto re-hits the natal Moon
June 30: Jupiter opposes natal Pluto
Expectations expanding, valuation jumping, speculation building.
At the same time, because this is Pluto, the move could be extreme.

I think this may be tied to the PIVOT-006 results.

From the chart, PIVOT-006 looks biased toward success. However, the natal Sun–Moon opposition is very tight. That suggests the company’s actual fundamentals/development results and shareholder/market psychology can easily clash.

That is the key risk I would watch.

[𝙱𝚒𝚘𝙷𝚘𝚛𝚘𝚜𝚌𝚘𝚙𝚎 @Biohoroscope]

$ELTX is entering an astrological configuration around May 31 to June 16 that suggests overheated valuation. This period looks extremely dramatic. In particular, June 11 to June 16 looks quite strong.

However, because Mars is striking Mercury and Uranus, this does not look like a clean, stable upward move. Rather, it appears to be a market phase in which either a sharp rally or a sharp drop could occur.

Around May 31, Jupiter squares the MC.

Around June 11, Mars conjuncts natal Mercury.

Around June 15, Mars conjuncts natal Uranus.

Around June 16, Jupiter conjuncts natal Venus.

Then, from around June 30 to July 17, $ELTX enters what appears to be one of the most significant judgment zones of 2026. This is where the expansion of expectations collides with reality. Since Jupiter is active, there may be expectation, expansion, and upward revaluation.

Around June 30, Jupiter opposes natal Pluto.

On July 8, the Vedic astrology dasha shifts from the Jupiter/Sun period to the Jupiter/Moon period.

Around July 10, Jupiter squares the natal North Node.

Around July 17, Jupiter squares natal Jupiter.

Because Jupiter is making square/opposition aspects to Pluto, the Node, and Jupiter, this looks highly excessive.

Around August 2–3, Jupiter conjuncts natal Mars and the Ascendant. This is a period when the company’s presence may expand all at once, and bullish material may be more likely to emerge. However, overreaction is also likely.

If this manifests positively, it would be a “revaluation.”

If it manifests negatively, it would be a “peak driven by expectations.”

[𝙱𝚒𝚘𝙷𝚘𝚛𝚘𝚜𝚌𝚘𝚙𝚎 @Biohoroscope]

$ELTX

If AMPLIFY-7P releases data in mid-June, there are signs that the data could contain an element of surprise. That said, there are no clear warning signs of failure around that period. There are, however, indications that the stock price could become volatile.

In particular, around June 15, Mars conjoins the natal Uranus.

Uranus represents surprises, sudden changes, and unexpected shifts in valuation. This suggests the event may not be treated as an ordinary data release. For better or worse, the market reaction could be sharp.

If the announcement slips into July, then in Vedic astrology, the company enters the Jupiter-Moon period from July 8 onward.

The Moon is in the 4th house and interacts with Ketu, which can bring fluctuations in market psychology, emotions, anxiety, and interpretation.

If the data comes out in June, the chart leans toward a favorable result, but the stock price may not respond in a straightforward way.

[𝙱𝚒𝚘𝙷𝚘𝚛𝚘𝚜𝚌𝚘𝚙𝚎 @Biohoroscope]

$CMPX
Ahead of the Moon/Venus period beginning on June 8, the tone around the stock price appears to be shifting.

From an astrological perspective, $CMPX looks clearly better in the second half of 2026. That said, caution is needed because a Venus period can also make something appear more attractive than its actual substance warrants.

Around June 11, there may be a sudden turning point in fate.

Around July 25–26, the company’s relationship with some counterpart or target may move significantly.

From around August 16–28, expectations may expand in a flashy way.

Around October 16–29, there may be a second major revaluation. Mercury retrograde is also involved here.

Around November 13–16, the company may come under closer scrutiny.

Around December 10–20, based on what has happened in 2026, the direction for 2027 and beyond may begin to solidify.

[𝙱𝚒𝚘𝙷𝚘𝚛𝚘𝚜𝚌𝚘𝚙𝚎 @Biohoroscope]

Let’s read CMPX’s 2026 chart. $CMPX

Around 4/25
A heavy judgment.
The basis is transiting Saturn opposing the natal Moon.

In a corporate chart, the Moon represents market psychology, shareholder sentiment, and public reception.
Saturn comes directly across from it.

Not excitement, but cooling.
Not expectation, but scrutiny.
Not optimism, but disappointment.
Even good news gets read coldly by the market.
Even if the statistics are positive, investors look for weaknesses and missed expectations.

Late April is not about “what the company released.”
It is about whether the market believes it.
Around 5/6
Pluto station.
This is extremely heavy.

Pluto is not the planet of surface-level news.
It digs into the bones of a company.
And in CMPX’s chart, Pluto comes very close to the natal Saturn, while also pressuring the Sun and Mars.

Saturn is the company’s foundation.
The Sun is its vitality.
Mars is the force that drives development forward.
So what is being tested here is not just a stock-price catalyst.

Can this company really survive?
Is this drug still worth advancing?
Does it have enough capital?
Does management still have another card to play?
May is the month when old expectations are burned away, and only the remaining value is examined.

Around 6/8
A shift in fortune.

In Vedic astrology, CMPX moves from the Moon/Ketu period into the Moon/Venus period around this time.
Ketu represents cutting away, stripping down, disappointment, emptiness, and the clearing of the past.

During a Moon/Ketu period, market psychology and the company’s explanation tend not to align.

The company may release something, but it does not land properly.
It easily turns into: why is this being sold off so hard?
But after 6/8, it enters the Moon/Venus period.

Venus represents appeal, valuation, partnerships, funding, reappraisal, and goodwill from the outside.

For a biotech company, this can appear as FDA dialogue, additional analysis, KOL-driven reassessment, hints of licensing or partnerships, or a reversal from excessive disappointment.
After being stripped down in April and May, June is when the story of “maybe there is still value left here” can begin.
Around 6/11
A sudden turn of fate.
This is a configuration where Uranus touches the nodes.

Uranus represents surprise, sudden change, external factors, and unexpected shifts in direction.
The nodes represent the company’s line of fate and the people or relationships tied to it.

So around 6/11, the shift does not feel like a normal, scheduled recovery.
It feels like the flow suddenly changes from the outside.
A partnership.
A strategic pivot.
FDA dialogue.
Additional analysis.
Reappraisal by experts.
Or the market suddenly deciding that “not everything was a failure.”

Around 7/25–7/26
Major contact with the outside environment.

Uranus opposes the Ascendant.
Saturn is also applying heavy pressure around the same time.

The Ascendant represents the company’s appearance, public face, and how it is seen by the market.

With Uranus directly opposite it, this does not look like the company quietly moving forward on its own.
It suggests disruption from outside parties: the market, regulators, competitors, investors, or counterparties.

A sharp rally is possible.
A sharp drop is also possible.

But since CMPX is already in the Moon/Venus period after June, this may not appear as pure destruction.
It could also show up as an external reappraisal or a shift in relationships.

In summary, CMPX’s April through July has a very strong narrative arc.

The company’s story does not feel finished with the April data release.

Astrologically, it looks more like this:

April: the market rejects it.
May: its survival power is tested.
June onward: investors begin asking what value still remains.
CMPX’s real answer does not come in April.
It comes after June.

Who picks up the ember from the ashes?

That is the next focus.

[𝙱𝚒𝚘𝙷𝚘𝚛𝚘𝚜𝚌𝚘𝚙𝚎 @Biohoroscope]

A potentially major turning point for $IDYA in 2026 is approaching.

[𝙱𝚒𝚘𝙷𝚘𝚛𝚘𝚜𝚌𝚘𝚙𝚎 @Biohoroscope]

$IDYA

Around June 4, Uranus will conjunct the natal Sun, marking what looks like one of the biggest turning points of 2026.

The Sun represents the company itself.

And Uranus overlapping with it looks like a configuration where the company’s very identity changes.

This feels like it could be a very powerful one.

Unexpected data.
A strategic shift.
A partnership.
Buyout speculation.
A sharp rally or collapse.
A dramatic change in how the market views the company.
Since OptimUM-02 full data is scheduled for an oral presentation at ASCO 2026 LBA9503 on June 1, this seems likely to be connected to that event.

[𝙱𝚒𝚘𝙷𝚘𝚛𝚘𝚜𝚌𝚘𝚙𝚎 @Biohoroscope]

$LPCN

In LPCN’s chart, Saturn is strong.

Saturn represents management, regulation, endurance, realistic development plans, and the persistence of the board and leadership team.

Because Jupiter enters this area cleanly, my reading is not that this is “a completely finished trial,” but rather that “there is a realistic path to restructuring and rebuilding.”

Furthermore, around May 28, Venus conjoins natal Jupiter.

This is a configuration where funding, buying interest, valuation, and a favorable reappraisal can easily come in.

[𝙱𝚒𝚘𝙷𝚘𝚛𝚘𝚜𝚌𝚘𝚙𝚎 @Biohoroscope]

@thisworldstinks
$VKTX
It looks like this could happen sometime between late February and early June 2027. It suggests an acquisition or partnership.

Around February 20, 2027: Jupiter sextiles natal Venus
Around March 2: Saturn trines natal Jupiter
Around March 22: Jupiter trines natal Uranus
Around May 2: Saturn sextiles natal Venus
Around May 5: Jupiter trines Uranus again
Around June 3: Jupiter sextiles Venus again

Acquisition speculation or rumors that serve as a prelude to this may emerge around September to October 2026.

If 2027 does not bring an acquisition, the next window would be 2029, but that looks more like a moment when the company becomes something entirely different.

[Anna's Biostock @thisworldstinks]

@Biohoroscope I would like to know the only thing that matters - is there going to be a buyout (either anytime in 2026 or 2027)?

[𝙱𝚒𝚘𝙷𝚘𝚛𝚘𝚜𝚌𝚘𝚙𝚎 @Biohoroscope]

$ASTS

For BlueBird 7 in April, Mercury, Mars, Saturn, and Neptune were indicating failure.

The next launch is in June. Around mid-June, Jupiter forms a sextile to the ASC and is roughly opposing Pluto, suggesting that the company’s presence will expand in the market. The ASC represents the company itself, the spacecraft, its visible form, and the way it steps out into the world. With Jupiter forming a supportive aspect to it, this strongly suggests “coming into public view,” “the spacecraft moving forward,” and “gaining attention and expanding.”

As a space-based communications infrastructure company, its “public stage” appears to be activated.

Recovering from April looks relatively easy.

[𝙱𝚒𝚘𝙷𝚘𝚛𝚘𝚜𝚌𝚘𝚙𝚎 @Biohoroscope]

$WVE
“The responding line changes from Siblings to Parent. The market initially enters through profit-taking and doubt, but then shifts toward examining the data itself.”

[𝙱𝚒𝚘𝙷𝚘𝚛𝚘𝚜𝚌𝚘𝚙𝚎 @Biohoroscope]

$WVE
The original hexagram is Mountain over Fire, Bi; the changing hexagram is Thunder over Fire, Feng. This suggests a flow in which presentation and framing move toward major attention, not a hexagram of bad data being met with silence.

However, the Parent line, representing the data, appears somewhat void. It is strong through Fire, but slow to take concrete form, meaning the market may not be able to reach an immediate conclusion at the time of the announcement.

The Child line, representing drug efficacy, is hidden as a伏神. This does not mean the drug is ineffective. Rather, it points to a type of efficacy that must be interpreted through biomarkers: M-AAT, Z-AAT, total AAT, dose response, durability, and suitability for accelerated approval.

The responding line changes from Siblings to Parent. The market initially enters through profit-taking and doubt, but then shifts toward examining the data itself.

[𝙱𝚒𝚘𝙷𝚘𝚛𝚘𝚜𝚌𝚘𝚙𝚎 @Biohoroscope]

@AgarradoJo17180 At least in 2026, I did not see any sign of that.

[𝙱𝚒𝚘𝙷𝚘𝚛𝚘𝚜𝚌𝚘𝚙𝚎 @Biohoroscope]

$RGNX
April 25: Uranus opposes natal Saturn
April 30: Mars opposes natal Mercury
May 4: Jupiter squares natal Uranus
May 5: Mars conjuncts natal Uranus

With these planetary movements lining up, I expect the RGX-202 data to be released by around May 13.

Saturn represents regulation, development plans, financing, and the company’s structural foundation. When Uranus hits that point, this is not simply a “good news” setup. It is an event that can break the existing framework of how the company is valued.
Jupiter squaring natal Uranus suggests speculation, surprise, sharp rallies or selloffs, and overreaction.
Mars conjunct natal Uranus points to sudden news, violent price action, and an extreme premarket reaction.

[𝙱𝚒𝚘𝙷𝚘𝚛𝚘𝚜𝚌𝚘𝚙𝚎 @Biohoroscope]

@thisworldstinks What kind of fate would you like to see for $VKTX?

[𝙱𝚒𝚘𝙷𝚘𝚛𝚘𝚜𝚌𝚘𝚙𝚎 @Biohoroscope]

$WVE
The original hexagram is Mountain over Fire, Bi; the changing hexagram is Thunder over Fire, Feng. This suggests a flow in which presentation and framing move toward major attention, not a hexagram of bad data being met with silence.

However, the Parent line, representing the data, appears somewhat void. It is strong through Fire, but slow to take concrete form, meaning the market may not be able to reach an immediate conclusion at the time of the announcement.

The Child line, representing drug efficacy, is hidden as a伏神. This does not mean the drug is ineffective. Rather, it points to a type of efficacy that must be interpreted through biomarkers: M-AAT, Z-AAT, total AAT, dose response, durability, and suitability for accelerated approval.

The responding line changes from Siblings to Parent. The market initially enters through profit-taking and doubt, but then shifts toward examining the data itself.